Inactive

NOI-NIAID-2014062 This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negoti... NOI-NIAID-2014062 This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an ther than full and open competition basis with PPD Development L.P. in Wilmington Delaware for testing human serum from participants of the VRC317 trial. They will be using custom assays to access responses to RSV Pre-F, Post-F, Ga, Gb and N viral proteins using the MSD Elisa platform. The Vaccine Research Center (VRC) at the National Institutes of Health (NIH) was established to facilitate research in vaccine development. The VRC is dedicated to improving global human health through the rigorous pursuit of effective vaccines for human diseases. The mission of the Vaccine Research Center (VRC) is to conduct research that facilitates the development of effective vaccines for human disease. The primary focus of research include: o HIV/AIDS Vaccine Development o Ebola Vaccine Development o Influenza Vaccine Development The overall objective of this project is to analysis human serum from participants of the VRC 317 trial using their custom assays to gain either acceptance or rejection. PPD is only one source that is capable of providing this service required at the level of quality required. Therefore PPD Labs must be the vendor through which this service provided. The use of the MSD assay platform is necessary to evaluate the human immune response to the VRC's pre-FRSV vaccine (DSCav-1) because it is s robust, efficient and proven method for evaluating antibody specificity, in response to the vaccine, in a systematic and high throughout manner otherwise unavailable to us in a research lab setting. The custom assay plates are to be used in this project are manufactured by AstraZeneca and proprietary. The proposed contractor, PPD Laboratories has given exclusive rights to use these assays. The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2014062) to Lorena Waller at Wallerlor@niaid.nih.gov, by 8:00 am eastern standard time, April 9, 2020. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.